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http://www.biomedcentral.com/1471-2393/14/317RESEARCH ARTICLE Open AccessEvaluation of the impact of universal testing for
gestational diabetes mellitus on maternal and
neonatal health outcomes: a retrospective
analysis
Diane Farrar1*, Lesley Fairley1, John Wright1, Derek Tuffnell3, Donald Whitelaw3 and Debbie A Lawlor2Abstract
Background: Gestational diabetes (GDM) affects a substantial proportion of women in pregnancy and is associated
with increased risk of adverse perinatal and long term outcomes. Treatment seems to improve perinatal outcomes,
the relative effectiveness of different strategies for identifying women with GDM however is less clear.
This paper describes an evaluation of the impact of a change in policy from selective risk factor based offering, to
universal offering of an oral glucose tolerance test (OGTT) to identify women with GDM on maternal and neonatal
outcomes.
Methods: Retrospective six year analysis of 35,674 births at the Women’s and Newborn unit, Bradford Royal
Infirmary, United Kingdom.
Results: The proportion of the whole obstetric population diagnosed with GDM increased almost fourfold
following universal offering of an OGTT compared to selective offering of an OGTT; Rate Ratio (RR) 3.75 (95% CI 3.28
to 4.29), the proportion identified with severe hyperglycaemia doubled following the policy change; 1.96 (1.50 to
2.58). The case detection rate however, for GDM in the whole population and severe hyperglycaemia in those with
GDM reduced by 50-60%; 0.40 (0.35 to 0.46) and 0.51 (0.39 to 0.67) respectively. Universally offering an OGTT was
associated with an increased induction of labour rate in the whole obstetric population and in women with GDM;
1.43 (1.35 to 1.50) and 1.21 (1.00 to1.49) respectively. Caesarean section, macrosomia and perinatal mortality rates in
the whole population were similar. For women with GDM, rate of caesarean section; 0.70 (0.57 to 0.87), macrosomia;
0.22 (0.15 to 0.34) and perinatal mortality 0.12 (0.03 to 0.46) decreased following the policy change.
Conclusions: Universally offering an OGTT was associated with increased identification of women with GDM and
severe hyperglycaemia and with neonatal benefits for those with GDM. There was no evidence of benefit or
adverse effects in neonatal outcomes in the whole obstetric population.
Keywords: Gestational diabetes, Universal and selective screening, Risk factors, Oral glucose tolerance test,
Perinatal outcomesBackground
Gestational diabetes mellitus (GDM) affects 2-6% of
pregnant women and is associated with increased risk
of important adverse perinatal outcomes, including
macrosomia and birth injury [1,2]. There is also evi-
dence of increased long term risk of type 2 diabetes [3]* Correspondence: diane.farrar@bthft.nhs.uk
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unless otherwise stated.and consequent cardiovascular disease in the mothers
[4] and possibly of increased long term risk of obesity
and associated adverse cardio-metabolic risk in off-
spring [5-8].
Evidence is increasing that treatment of GDM improves
perinatal outcomes [9] supporting the case for improved
identification of women with GDM. There is debate how-
ever about the relative effectiveness of different strategies
for identifying women with GDM, largely because of thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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clinical guidelines and practice for detecting GDM be-
tween, and within, countries. Strategies include: case by
case assessment [10], selective (75 g or 100 g) oral glucose
tolerance testing of high risk women identified using spe-
cific risk factors or a 50 g glucose challenge test [11] and
universal testing, i.e. offering all women an oral glucose
tolerance test (OGTT) [12].
To date in the United Kingdom (UK) there has been no
recommendation to offer all women an OGTT, in prac-
tice, and more recently in clinical guidelines, selective test-
ing of high risk women has been undertaken. Prior to
2008 in the UK there was no national recommended
screening strategy to identify women with GDM. Screen-
ing if it was conducted, was at the discretion of the clin-
ician and based on variable use of risk factors [13-15].
When risk factor screening was undertaken, a two-step
approach was preferred: clinicians made a clinical assess-
ment of each woman’s risk and offered a two hour 75 g
OGTT to identify GDM, with a diagnosis based on the
World Health Organisation (WHO) criteria [16].
Since 2008 UK national clinical guidance has recom-
mended that all women are screened by assessment of
specific risk factors at their first pregnancy appointment.
Any pregnant woman (not previously identified as having
type 2 diabetes) with one or more risk factor: family his-
tory of diabetes; South Asian; black or middle eastern eth-
nicity; previous history of having a baby with macrosomia;
or body mass index (kg/m2) (BMI) ≥30, should be offered
an OGTT between 24 and 28 weeks gestation [11].
The American College of Obstetricians and Gynecolo-
gists (ACOG) also recommends a two-step approach.
Women are screened for GDM at 24 to 26 weeks, either
by patient history, risk factors or 50 g one hour glucose
challenge test and if screen positive offered a 100 g
OGTT. GDM diagnosis is made using criteria from
Carpenter and Coustan or the National Diabetes Data
Group [17]. By contrast the International Association of
Diabetes in Pregnancy Study Group [12] (indorsed by
the American Diabetes Association) recommend all women
not previously identified as having type 2 diabetes (irre-
spective of risk factors) are offered a diagnostic 75 g OGTT
at 24–28 weeks. GDM is diagnosed if any one of plasma
glucose levels are >5.0 mmol/l, one hour >9.9 mmol/l or
two hour >8.4 mmol/l is found [18].
Current screening recommendations are based on evi-
dence from observational studies with no evidence that
diagnosis using any of the above strategies improves
perinatal or long term adverse outcomes or is cost-
effective. Consequently the US Preventative Services
Taskforce recommends clinicians discuss screening for
GDM with each woman and case by case decisions made
based on risk status [10]. Selectively offering women an
OGTT based on risk factor assessment and universallyoffering an OGTT to some extent represent the extremes
of possible approaches for identifying women at risk. The-
oretically the former approach may have a high false nega-
tive rate and miss the opportunity to prevent adverse
perinatal outcomes in women at risk, whereas the latter
approach may over-diagnose [19], cause unnecessary anx-
iety [20] and may not be cost-effective in improving peri-
natal outcomes. Recent policy changes from a clinician led
risk factor screening approach to universal offering a diag-
nostic 75 g OGTT in Bradford provided us with the op-
portunity to compare these two approaches.
Setting
Bradford is a city in the North of England with high levels
of deprivation. Approximately half of births are to women
of South Asian origin and a fifth of White British pregnant
women are obese (unpublished routine study hospital data
from 2012). In response to the Bradford District Mortality
Commission, which was undertaken in 2006 and
highlighted rising infant mortality and the poor health of
pregnant women in the city [21], a number of changes to
clinical practice were implemented, including offering a
diagnostic OGTT to all pregnant women at 26–28 weeks
gestation. Prior to 2007 women were offered an OGTT
at 26–28 weeks gestation following individual assess-
ment of risk status. The aim of this study was to eva-
luate the policy change from case by case risk factor
based assessment and selective testing to universal test-




We conducted a before and after comparison using data
from all women who gave birth at the Bradford Royal
Infirmary between 2004 to 2006 (before group) and
2008 to 2010 (after group). Those who gave birth in
2007 were excluded as this year contained a mixture of
women selectively offered an OGTT and women univer-
sally offered an OGTT. In the UK, anonymised routinely
collected data of those accessing National Health Service
care may be used to evaluate service provision. Those
using such data for service evaluation are not required
to obtain verbal or written consent from patients or ob-
tain ethical approval. Therefore neither patient consent
nor ethical approval for this study was obtained, as rou-
tinely collected hospital data were used to evaluate ser-
vice provision. Analyses were conducted on a completely
anonymised dataset and none of the authors had access
to any patient identifiers [22].
Oral glucose tolerance test
The 75 g OGTT was administered during the study
period between 26–28 weeks gestation. Fasting plasma
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ments were obtained. Criteria used to diagnose GDM was
based on WHO recommendations (i.e. either fasting
glucose ≥6.1 mmol/L or two-hour glucose ≥7.8 mmol/L)
and did not change throughout the study period [16].
Extraction of data
Data were extracted from hospital written and electronic
medical records. Maternal risk factors (previous GDM,
family history of diabetes, previous history of giving
birth to a baby with macrosomia, obesity, South Asian
or black ethnicity, glycosuria, raised result of any ran-
dom blood glucose test and increased liquor volume)
were available for women who had completed an OGTT
between 2004 to 2006 (case by case assessment and se-
lectively tested group). These risk factors were not avail-
able for women during this time period that did not
complete an OGTT, nor were they available for women
who were pregnant after 2007, other than ethnicity
which was available for all women. Data on whether an
OGTT was performed, whether they were diagnosed
with GDM and maternal and neonatal outcomes (induc-
tion of labour, caesarean birth, macrosomia (birth weight
equal to or greater than 4 kg), perinatal mortality, ad-
mission to neonatal unit, Erb’s palsy, fractured clavicle,
were available for all births (before and after the policy
change) and included in the analyses.
Data on risk factors (where available), completion of
the OGTT and OGTT results were abstracted from
paper medical or electronic records, outcome data were
provided by the hospital electronic records system for
the period 2004 to 2006. Neonatal transitional care unit
data and data for 2008 to 2010 were abstracted from
paper medical or electronic records. Research midwives
abstracted data from paper records using a pre-prepared
coded data extraction sheet. A 5% random sample of
these data were independently abstracted by a research
fellow; for all field codes there was greater than 98%
agreement between the research fellow and research
midwife abstractions. Electronic data were transferred
from the electronic medical record to a research database
and merged with the abstracted paper record data. These
electronic data were manually checked against stored
paper records and again high levels (98%) of agreement
were found. We also compared the medical records of
GDM diagnoses with the biochemical laboratory re-
cords of test results and found very high levels of
agreement (>99%).
Analysis
All analyses were conducted using Stata version 10 [23].
We calculated the percentage of women with an identi-
fied risk factor and used the binomial distribution to cal-
culate 95% confidence intervals for these prevalence’s.We used the same method to calculate the percentage
and 95% confidence intervals for women who had an
OGTT between 2008 and 2010 (i.e. period during which
there was a policy of universal OGTT testing).
The proportion of women with GDM, either a fasting
blood glucose ≥6.1 mmol/L, or a two hour blood glu-
cose ≥7.8 mmol/L or both and of these the proportion
with severe hyperglycaemia, either a fasting blood glu-
cose ≥7 mmol/L, or a two hour blood glucose ≥11.1 mmol/L
or both was estimated. The proportion of women/in-
fants with each risk factor (where available) and out-
come (diagnosis of GDM, induction of labour, caesarean
birth, macrosomia, perinatal mortality, admission to
neonatal unit, Erb’s palsy and fractured clavicle) was esti-
mated for each time period. Rate ratios (RR), comparing
outcomes after the introduction of the universal offer of a
diagnostic OGTT, to those before this policy, together
with their 95% confidence intervals were estimated using
the epitab command in Stata [23].
Results
Between 2004 and 2006 (selectively offered group), 17,160
women gave birth; 1162 (7%) were offered an OGTT
following risk assessment by their clinician and 1151
completed the test (7% of all women and 99% of those
offered the test). Between 2008 and 2010, (universally
offered group) 18,514 women gave birth, 18,328 (99%)
were offered an OGTT and 11,516 completed the test
(62% of all women and 63% of those offered the test)
(Table 1). For births occurring between 2004–2006,
amongst those who completed the OGTT 58% were
from an ethnic group with increased risk (the most
common risk factor) compared with 55% after the pol-
icy change (risk ratio 0.95, 95% CI: 0.87 to 1.03). Obes-
ity was the second most common individual risk factor
for women selectively offered an OGTT (Additional
file 1: Table S1). A small proportion (1%) of the women
in the universally offered group were not offered an
OGTT, reasons were: pre-existing diabetes or late at-
tendance for antenatal care. Of those attending for the
OGTT (after group only), 3% did not complete the test
either because they had been unable to fast overnight
or were unable to drink the glucose solution due to
nausea. These women were all offered a second ap-
pointment and over 99% completed the test at that sec-
ond appointment.
The proportion diagnosed with GDM increased almost
fourfold after the introduction of the policy of offering a
diagnostic OGTT to all pregnant women compared to
selectively offering the test, (2% to 6%) Rate Ratio (RR)
(3.75 95% CI 3.28 to 4.29) (Table 1). The proportion
identified as having severe hyperglycaemia doubled fol-
lowing the change in policy (0.5% to 1.0%, 1.96 1.50 to
2.58) (Table 1). However, the population case detection
Table 1 Association between selective and universal offer of an oral glucose tolerance test (OGTT) with gestational
diabetes and severe hyperglycaemia detection rate (number tested with percentage of whole population and
percentage of screened population in parenthesis)
Selective offering of an OGTT Universal offering of an OGTT
2004 2005 2006 2004-2006 2008 2009 2010 2008-2010 Rate ratio comparing
detection rates after to
before (95% CI) for the




5512 5784 5864 17160 6162 6251 6101 18514
Completed OGTT 323 (6) 299 (5) 529 (9) 1151 (7) 3797 (62) 3947 (63) 3772 (62) 11516 (62)
GDMa identified 62 (1, 19) 83 (1, 28) 135 (2, 26) 280 (2, 24) 311 (5, 8) 398 (6, 10) 423 (7, 11) 1132 (6, 10) 3.75 (3.28 - 4.29)




21 (0.4, 34) 33 (0.6, 40) 29 (0.5, 21) 83 (0.5, 30) 46 (0.7, 14) 63 (1.0, 16) 63 (1.0, 16) 172 (1.0, 15) 1.96 (1.50 - 2.58)
0.51 (0.39 - 0.67)
OGTT = oral glucose tolerance test.
GDM = gestational diabetes mellitus, CI = confidence interval.
aGDM = either a fasting blood glucose ≥6.1 mmol/L, or a two hour blood glucose ≥7.8 mol/L or both.
bSevere hyperglycaemia = either a fasting blood glucose ≥7 mmol/L, or a two hour blood glucose ≥11.1 mmol/L or both.
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with GDM) reduced by 50-60% following universal offer-
ing of a diagnostic OGTT, reflecting an increase in those
offered the test who were not at risk (Table 1).
Table 2 shows the testing strategies comparison of ad-
verse maternal and neonatal outcomes. Induction of
labour rate increased both in the whole obstetric popula-
tion and in women with GDM after the introduction of
offering universal OGTT. The caesarean section rate in
the whole population was similar before and after the
introduction of offering universal OGTT, but introduc-
tion of this universal offer was associated with a reduc-
tion in caesarean section rates amongst those with
GDM. Similarly, offering universal OGTT was not asso-
ciated with a change in the rate of macrosomia in the
whole obstetric population, but was associated with aTable 2 Association between selective and universal offer of














Induction of labour 2422 (14.1) 3678 (20.0) 1.43 (1.35- 1
Caesarean birth 3477 (20.3) 3709 (20.0) 1.00 (0.96-1
Macrosomia (birth
weight ≥4 kg)
1105 (6.4) 1219 (6.6) 1.04 (0.95-1
Perinatal mortality 228 (1.3) 212 (1.1) 0.86 (0.71-1
Admitted to NNU 1670 (9.7) 1497 (8.1) 0.83 (0.77-0
Erb’s palsy 7 (0.04) 12 (0.06) 1.59 (0.58-4
Fractured clavicle 4 (0.02) 6 (0.03) 1.39 (0.33-6
OGTT = oral glucose tolerance test.
NNU: neonatal unit; *insufficient numbers to perform analyses for these outcomes imarked reduction in its rate amongst those with GDM.
There was also a reduction in perinatal mortality for
women with GDM after the introduction of the policy
and some evidence of a weaker reduction in the whole
population, but the latter rate ratio had wide confidence
intervals that included the null value.
Offering universal OGTT was also associated with
a reduced rate of admission to the neonatal unit for
the whole obstetric population and amongst those
with GDM. The rates of Erb’s palsy and fractured
clavicle in the infants appeared similar before and
after the policy change, but at both time points rates
of these outcomes were very low and the ratio esti-
mates have very wide confidence intervals that in-
clude any association from a marked reduction to a
marked increase in risk.an OGTT to identify gestational diabetes and risk of
tric population and in women with gestational diabetes




Selective offer of an
OGTT 2004–2006
N = 280 N (%)
Universal offer of an
OGTT 2008–2010





.50) 120 (42.9) 587 (51.9) 1.21 (1.00-1.49)
.05) 122 (43.6) 345 (30.5) 0.70 (0.57-0.87)
.12) 45 (16.1) 50 (4.4) 0.22 (0.15-0.34)
.04) 4 (1.4) 8 (0.7) 0.12 (0.03-0.46)
.89) 69 (24.6) 118 (10.4) 0.42 (0.31-0.58)
.76) * * *
.70) * * *
n those identified with gestational diabetes.
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Changing antenatal care policy to identify women with
GDM from case by case assessment and selective diag-
nostic OGTT, to offering a diagnostic OGTT to all preg-
nant women was associated with increased rates of
GDM diagnoses and severe hyperglycaemia in the whole
obstetric population, but with lower detection rates in
those who completed the OGTT. This suggests universal
offer of OGTT is associated with the increased identifi-
cation of mild-moderate hyperglycaemia. There was also
a reduction from 94% to 63% of those offered a diagnos-
tic OGTT who accepted and completed the test. Induc-
tion of labour rate in the whole obstetric population and
in those diagnosed with GDM increased when all
women were offered a universal diagnostic OGTT, with
no overall increase in caesarean section rate and a de-
crease in those with GDM. Offering all women diagnos-
tic testing was also associated with improved neonatal
outcomes in women identified with GDM, including a
marked reduction in rates of macrosomia, neonatal mor-
tality and admissions to neonatal care.
There was no strong evidence that offering an OGTT
to all women affected most outcome rates for the whole
obstetric population. There was some suggestion that
perinatal mortality may have reduced in the whole ob-
stetric population following the policy change, but here
the confidence intervals were wide and just included the
null value.
Thus, overall these results suggest that universal testing
with OGTT in a high risk population such as that in
Bradford with a large proportion at risk because of their
ethnicity or obesity has some beneficial effects in terms of
reducing adverse perinatal outcomes in those identified
with GDM, without increasing caesarean section rates or
adverse neonatal outcomes in the whole obstetric popu-
lation. There were no changes to treatment policy dur-
ing the study period that could account for the
differences in outcomes demonstrated. A ‘step up’ ap-
proach was followed depending on severity of hypergly-
caemia, whereby diet and exercise modification was
advised and metformin and/or insulin added accordingly.
The reduced uptake of the invitation for a universally
offered OGTT is similar to other studies who have re-
ported rates of 58% [24] and 73% [25] and may reflect a
difference in attitudes to a test once it is offered to
everyone. It is plausible that both health care practi-
tioners and the women themselves see the test as less
important when it is not restricted to those designated
as high risk following individual assessment. For ex-
ample, in the absence of risk factors health professionals
may place less emphasise on the importance of the test.
Unfortunately, we did not have detailed information on
risk factors in both those attending antenatal care before
and after the change in policy to examine whetheruptake amongst the most at risk had changed over time.
It is also possible that those who declined the test were
different in some way to those who accepted the test
offer and that any benefits of universal testing may be
greater if uptake could be improved from 63%, though
we are unable to examine this here. Uptake of OGTT
offer however may increase over time as clinicians and
women become more familiar with the test and reasons
for testing.
The potential benefits of offering universal testing and
treatment of cases must be weighed against the cost of
this service and any possible adverse effects to the preg-
nant women. Criteria for GDM diagnosis did not change
across the study period, however it is notable that before
the introduction of universal diagnostic testing three
women were tested for each woman diagnosed with
GDM, whereas once universal invitation was introduced
ten women were tested for each woman diagnosed. If it
were possible to increase the uptake of testing with uni-
versal invitation this difference would likely increase.
The small proportion at both time points of women
who presented for the test, but could not complete it,
because they had not fasted or were nauseous following
drinking the glucose solution suggests that once a
woman has decided to accept the invitation the test is
feasible in the vast majority. We are unable in this study
to examine cost-effectiveness as we do not have compre-
hensive data on the extent of risk factor screening that
was completed in all women in the before group and
since this is a before and after comparison we are only
able to assess association rather than causation/effect.
There were no changes to criteria thresholds for GDM
diagnosis within the study period, which would be likely
to affect prevalence of GDM, [26] even so prevalence in-
creased irrespective of strategy used. The increasing
prevalence of maternal obesity and an increasing aware-
ness amongst clinicians of the association between obes-
ity and poor pregnancy outcomes may be responsible for
the changes seen. For example, in 2004 three women
were tested for GDM because of a raised BMI, in 2005,
17 women and in 2006, 225 women. Different risk fac-
tors are associated with different degrees of risk for
GDM development. South Asian ethnicity and family
history of diabetes carry greater risk of GDM develop-
ment compared with BMI ≥30 [27]. However, we found
no difference in the proportion of women who com-
pleted the OGTT before and after introduction of uni-
versal testing who belonged to an at-risk ethnic group,
which is perhaps surprising as 50% of the study popula-
tion are of South Asian ethnicity, this may reflect a belief
that the use of ethnicity as a risk factor would result in
too great a cost burden at the study hospital prior to the
policy change or that the risk conveyed was not great
enough to necessitate screening.
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of women who are diagnosed with GDM are consistent
with randomised trials of more intensive treatment of
GDM, suggesting that the increased detection rates did
result in effective treatment in those with GDM. For ex-
ample, recent randomised trials suggest that intensive
treatment effectively reduces macrosomia and other ad-
verse neonatal outcomes [28,29]. With respect to mater-
nal outcomes these trials had different findings, with one
showing intensive treatment resulted in an increase in
induction rates (as in our study), but no effect on caesar-
ean section rates [28] and the second, no difference in
induction rate and a reduction in caesarean section rates
(the latter as in our study) [29].
The reduction in rates of macrosomia, comparing
births after the introduction of universal offering of
OGTT to those before is also consistent with substantial
evidence that maternal hyperglycaemia causes increased
birth size overall and increased adiposity at birth [8,30].
Macrosomia complicates the intrapartum, rather than
the antenatal period, and is therefore more likely to be
associated with birth trauma and arrested labour rather
than perinatal mortality [31]. In our study population
the numbers experiencing birth trauma (Erb’s palsy or
fractured clavicle) were too few to make meaningful
conclusions about the change in policy to offering uni-
versal testing.
Implications for research
Further research is needed to understand why, when all
women were offered an OGTT only 63% attended for
the test, compared with 99% when the OGTT was only
offered to those identified as at risk. It is also important
to investigate what the effect of increasing uptake of the
test might be. Ultimately, randomised trials that com-
pare universal testing and selective testing and assess-
ment of a range of perinatal outcomes are required,
but such trials would require a very large sample size.
Continued evaluation of the Bradford population and
other similar populations where there is a policy
change provide some evidence of the likely impact of
universal testing. It is also important to include assess-
ment of the cost-effectiveness of strategies to identify
and treat GDM, on-going work may help to answer
this question [32].
Strengths and limitations
A key strength of our study is its ability to examine the
association of offering universal testing for OGTT com-
pared with a more conservative strategy of selective test-
ing based on individual assessment of risk. We were able
to include in our analyses all women giving birth in
Bradford over the study period examined and therefore
results are unlikely to be affected by selection bias andthe numbers included in the analyses are large. This ap-
proach provides a ‘real life’ evaluation of what happens
when health care policy is changed, rather than findings
from randomised trials that may overestimate the effect
of an intervention [33,34]. Whilst routine clinical data
may be less accurate than data collected specifically for
research purposes we carefully checked the reliability of
data from different sources, where possible (e.g. elec-
tronic and paper medical records and laboratory results)
and completed an independent abstraction of a random
sample of data from medical records to improve the val-
idity of the data we have used here.
The main weakness of this study is that it is a before
and after comparison and therefore we cannot assume
that any associations are caused by the change in policy
of offering an OGTT to all pregnant women. For 2006
to 2008 we only had access to aggregated data for out-
comes therefore we could only examine unadjusted asso-
ciations and not adjust analyses to take account of the
individual level background characteristics and con-
founders of the population and how these might have
changed over time. Although there were no other
changes in policy, any other characteristic that changed
over this period could explain the findings we have ob-
served (i.e. could have confounded our assumed associ-
ation of change to universal offering of an OGTT with
the outcomes assessed). For example, there was an in-
crease in induction of labour rate following the introduc-
tion of universal offer of an OGTT, both for the whole
obstetric population and for those with GDM, which
cannot be wholly accounted for by the increase in GDM
diagnosis.
As noted above there was already evidence that the
rate of diagnosis of GDM was increasing prior to the
change in policy, but the rate of this increase was much
more marked after the policy was introduced. Despite
the increasing rates of diagnosis before the policy
change, there were still improved outcomes for the
group universally offered an OGTT compared to the
group selectively offered an OGTT.
Data on detailed risk factor assessment for all women
across the whole period was not available; data were only
available for those in the before group who completed
an OGTT. Thus, we were unable to examine how well
risk factor screening was implemented before the offer
of universal testing or to compare risk factors between
those who completed an OGTT and those who declined
the invitation after the policy change. As noted above we
are unable to complete a cost-effectiveness analysis in
this study. Lastly, the population of Bradford are a high
risk group as half of births are to women of South Asian
origin and a fifth of the non-South Asian population are
obese. Thus, at least 60% of this population would have
at least one risk factor deemed by the NICE guidelines
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[11]. We cannot conclude that the results found in this
population would necessarily generalise to other popula-
tions or to populations where other strategies or criteria
are used, but given the whole population coverage it is
likely that they would generalise to populations with
similar high levels of risk.
Conclusion
Our results suggest that offering all women an OGTT
was associated with increased identification of women
with GDM and severe hyperglycaemia and with neonatal
benefits for those with GDM. There was no evidence of
clear differences in neonatal outcomes in the whole ob-
stetric population, which is perhaps not surprising as
only 6% were identified as having GDM when an OGTT
was offered to all women and GDM diagnosis made
based on the WHO criteria.
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